BR9711315A - Composi-Æo farmac-utica contendo cidos 4-oxobutanÄicos - Google Patents

Composi-Æo farmac-utica contendo cidos 4-oxobutanÄicos

Info

Publication number
BR9711315A
BR9711315A BR9711315A BR9711315A BR9711315A BR 9711315 A BR9711315 A BR 9711315A BR 9711315 A BR9711315 A BR 9711315A BR 9711315 A BR9711315 A BR 9711315A BR 9711315 A BR9711315 A BR 9711315A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
composition containing
oxobutanoic acids
oxobutanoic
acids
Prior art date
Application number
BR9711315A
Other languages
English (en)
Inventor
Gerard Moinet
Lillian Doare
Micheline Kergoat
Philippe Maizeray
Didier Mesangeau
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR9711315A publication Critical patent/BR9711315A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR9711315A 1996-08-16 1997-08-05 Composi-Æo farmac-utica contendo cidos 4-oxobutanÄicos BR9711315A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9610254A FR2752422B1 (fr) 1996-08-16 1996-08-16 Composition pharmaceutique contenant des acides 4-oxo-butanoiques
PCT/EP1997/004252 WO1998007681A1 (fr) 1996-08-16 1997-08-05 Compositions pharmaceutiques contenant des acides 4-oxo-butanoiques

Publications (1)

Publication Number Publication Date
BR9711315A true BR9711315A (pt) 1999-08-17

Family

ID=9495089

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711315A BR9711315A (pt) 1996-08-16 1997-08-05 Composi-Æo farmac-utica contendo cidos 4-oxobutanÄicos

Country Status (29)

Country Link
US (1) US6143787A (pt)
EP (1) EP0925273B1 (pt)
JP (1) JP3105545B2 (pt)
KR (1) KR100488430B1 (pt)
CN (1) CN1082370C (pt)
AR (1) AR009251A1 (pt)
AT (1) ATE208364T1 (pt)
AU (1) AU725440B2 (pt)
BR (1) BR9711315A (pt)
CA (1) CA2263348C (pt)
CY (1) CY2298B1 (pt)
CZ (1) CZ294165B6 (pt)
DE (1) DE69708130T2 (pt)
DK (1) DK0925273T3 (pt)
ES (1) ES2166098T3 (pt)
FR (1) FR2752422B1 (pt)
HU (1) HUP0004223A3 (pt)
ID (1) ID17875A (pt)
NO (1) NO312290B1 (pt)
PL (1) PL187371B1 (pt)
PT (1) PT925273E (pt)
RU (1) RU2175966C2 (pt)
SI (1) SI0925273T1 (pt)
SK (1) SK283055B6 (pt)
TR (1) TR199900329T2 (pt)
TW (1) TW438764B (pt)
UA (1) UA57031C2 (pt)
WO (1) WO1998007681A1 (pt)
ZA (1) ZA977327B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04318852A (ja) * 1991-04-18 1992-11-10 Fujitsu Ltd レジスト・パターン形成方法
KR100965201B1 (ko) 2001-06-12 2010-06-24 웰스테트 테라퓨틱스 코포레이션 대사 질환의 치료용 화합물
FR2832633B1 (fr) * 2001-11-28 2004-09-24 Lipha Composition pharmaceutique comprenant une association metformine et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete
FR2832925B1 (fr) * 2001-12-03 2006-07-14 Lipha Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation
FR2834214B1 (fr) * 2001-12-28 2004-09-24 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete
FR2834640B1 (fr) * 2002-01-11 2004-09-24 Lipha Composition pharmaceutique comprenant une glitazone et un acide 4-oxobutanoique et son utilisation pour traiter le diabete
AU2003286728A1 (en) * 2002-11-01 2004-06-07 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
ATE468114T1 (de) * 2002-11-08 2010-06-15 High Point Pharmaceuticals Llc Sichere chemische entkuppler zur behandlung von fettsucht
FR2849599B1 (fr) * 2003-01-07 2006-12-29 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
KR101127390B1 (ko) * 2003-04-15 2012-03-23 웰스태트 테러퓨틱스 코포레이션 대사 질환의 치료용 화합물
ATE522209T1 (de) 2007-12-03 2011-09-15 Merck Patent Gmbh Verwendung von 4-oxobutansäure-derivaten bei der behandlung von mit immunologischen leiden verbundenen erkrankungen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1190340B (it) * 1986-06-06 1988-02-16 Roussel Maestretti Spa Derivati dell'acido 4-fenil 4-osso 2-butenoico,loro procedimento di preparazione e loro impiego come prodotti medicinali
US5250517A (en) * 1987-10-06 1993-10-05 Hoffmann-La Roche Inc. Renin inhibiting compounds
DK523288A (da) * 1987-10-06 1989-04-07 Hoffmann La Roche Aminosyrederivater
US5055466A (en) * 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
CA1329680C (en) * 1987-11-23 1994-05-17 Harold Norris Weller, Iii N-heterocyclic alcohol derivatives
FR2733750B1 (fr) 1995-05-03 1997-06-13 Synthelabo Derives de l'acide gamma-oxo-alpha-(phenylmethyl)-5,6- dihydro-4h-thieno(3,4-c)pyrrole-5-butanoique, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
EP0925273B1 (fr) 2001-11-07
JP3105545B2 (ja) 2000-11-06
CZ294165B6 (cs) 2004-10-13
WO1998007681A1 (fr) 1998-02-26
FR2752422A1 (fr) 1998-02-20
ZA977327B (en) 1998-03-30
PL187371B1 (pl) 2004-06-30
ES2166098T3 (es) 2002-04-01
JP2000506543A (ja) 2000-05-30
AR009251A1 (es) 2000-04-12
AU3942297A (en) 1998-03-06
CA2263348A1 (fr) 1998-02-26
NO990707D0 (no) 1999-02-15
CN1082370C (zh) 2002-04-10
EP0925273A1 (fr) 1999-06-30
HK1021728A1 (en) 2000-06-30
PT925273E (pt) 2002-04-29
RU2175966C2 (ru) 2001-11-20
SI0925273T1 (en) 2002-04-30
ATE208364T1 (de) 2001-11-15
UA57031C2 (uk) 2003-06-16
AU725440B2 (en) 2000-10-12
CA2263348C (en) 2008-05-13
TW438764B (en) 2001-06-07
TR199900329T2 (xx) 1999-04-21
US6143787A (en) 2000-11-07
SK283055B6 (sk) 2003-02-04
KR100488430B1 (ko) 2005-05-10
SK18099A3 (en) 2000-03-13
KR20000068106A (ko) 2000-11-25
NO312290B1 (no) 2002-04-22
CN1227538A (zh) 1999-09-01
NO990707L (no) 1999-02-15
DE69708130T2 (de) 2002-06-20
CZ49899A3 (cs) 1999-05-12
CY2298B1 (en) 2003-07-04
HUP0004223A3 (en) 2001-12-28
PL331645A1 (en) 1999-08-02
DK0925273T3 (da) 2002-02-18
FR2752422B1 (fr) 1998-11-06
ID17875A (id) 1998-02-05
HUP0004223A2 (hu) 2001-04-28
DE69708130D1 (de) 2001-12-13

Similar Documents

Publication Publication Date Title
FI20071025L (fi) Farmaseuttisia koostumuksia
NO20004345L (no) Farmasøytisk sammensetning
ID18352A (id) Komposisi-komposisi farmasi
FI991302L (fi) Parannetut farmaseuttiset koostumukset
PT925273E (pt) Composicoes farmaceuticas contendo acidos 4-oxobutanoicos
EE9800400A (et) Diklofenaaki sisaldavad farmatseutilised kompositsioonid
BR9507768A (pt) Composição farmacêutica
ID16781A (id) Formulasi-formulasi farmasi
EE9900206A (et) N-sulfonüülindoliiniderivaate sisaldavad farmatseutilised kompositsioonid
ID29294A (id) Komposisi farmasi
LV11727A (lv) Farmaceitiska kompozicija
ID18698A (id) Komposisi farmasi
ID25857A (id) Komposisi farmasi
ITMI942166A0 (it) Composizioni farmaceutiche miorilassanti
FI973280A0 (fi) Farmaseuttinen koostumus
ITMI962628A0 (it) Composizione farmaceutica
BR9605777A (pt) Composição farmacêutica
FI962738L (fi) Farmaseuttiset koostumukset
FI954050L (fi) Lääkekoostumuksia
ID23531A (id) Komposisi farmasi
BR9605131A (pt) Composição farmacêutica
IT1272935B (it) Composizione farmaceutica contenente n-acetil-cisteina
SE9601854D0 (sv) Farmaceutisk komposition
ID17133A (id) Komposisi farmasi
SE9604299D0 (sv) Pharmaceutical composition

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 14A, 15A, 16A, 17A, 18A, 19A E 20A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2605 DE 08-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.